A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients.

@article{Patrizi2008ADR,
  title={A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients.},
  author={Annalisa Patrizi and Bruno Capitanio and Iria Neri and Federica Giacomini and Jo Linda M Sinagra and Beatrice Raone and Enzo Berardesca},
  journal={Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology},
  year={2008},
  volume={19 7},
  pages={619-25}
}
A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. Using the Investigator's Global Assessment (IGA) score for AD, patients with a score of 2 (mild) or 3 (moderate) were enrolled in the study. Patients were randomly selected to receive MAS063DP (20 patients), MAS060 (20 patients, a similar formulation with lower key… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Telmesteine exerts an anti-protease activity suitable in the therapy of psoriasis. Poster session in: 21st World Congress of Dermatology - Buenos Aires 01-05/October/2007

  • S Gariboldi, M Mastrodonato, C. Rumio
  • 2007

Efficacy of a topical agent, MAS063D ( Atopiclair ), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis

  • H Zhai, CD Villarama, ZH Hafeez, HI. Maibach
  • Exog Dermatol 2003:
  • 2003
1 Excerpt

Similar Papers

Loading similar papers…